INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance
INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance Yahoo Finance
Covered in this story
What has happened since
- Insmed is down 2.3% since this was published, 5 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Insmed
- Goldman Sachs: $122 → $188 by Sep 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $INSM yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Insmed →Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.